Bio News
Hanmi Pharmaceutical has licensed HM17321, a long-acting UCN2 analog, to Genentech in the United States. The total contract value is $2.305 billion (approximately 3.1892 trillion won), and Hanmi Pharmaceutical will initially receive an upfront payment of $190 million. Hanmi Pharmaceutical will also receive an additional $2.115 billion in milestone payments tied to clinical development, regulatory approval and commercialization, as well as royalties.
BIOBOOK TEAM
biobookmedia@biobook.co.krIonkura Reports 20.8-Month Median Survival in Phase 1 Trial for Metastatic Eye Cancer
Verastem’s VS-7375 Shows Response Rates of Up to 50% in Pancreatic Cancer; Phase 3 Trial to Begin This Year
Pfizer to Co-Develop Sec61 Inhibitors With Enodia in Deal Worth Up to $500 Million
Galderma to Acquire ZO Skin Health for $1.5 Billion, Expanding Dermatology Portfolio
Verdiva halts GLP-1 transition trial, citing ‘market changes’
Stryker to Invest $400 Million in CMR Surgical, Expand Robotic Surgery
